Acute Stroke as Initial Manifestation of Essential Thrombocytosis in a 77-Year-Old Filipino Female: A Case Report

Frances Marie C. Tamayo, Vicente G. Rosales Jr., Jojo R. Evangelista

Oct 2025 DOI 10.35460/2546-1621.2025-0027     Access   

Abstract

Essential thrombocytosis (ET) is one of the myeloproliferative neoplasms (MPNs) which increase the probability of thrombosis and bleeding. ET is usually discovered as an incidental finding on blood workup and in rare cases, will present as vascular events such as stroke. Our patient, a 77-year-old female, a case of acute cerebral infarct presented with numbness and severe weakness of left upper and lower extremity. Serial complete blood count showed an elevated platelet count. Bone marrow aspiration studies showed increased number of enlarged megakaryocytes. She was diagnosed as a case of ET and maintained on Aspirin 80 mg per tablet once a day and Hydroxyurea 500 mg per tablet once a day.

Keywords: Essential thrombocytosis, Myeloproliferative neoplasms, Acute cerebral infarct, Aspirin, Hydroxyurea

  1. Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, et al. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Neth J Med [Internet]. 1999;54(2):46–62. Available from: https://doi.org/10.1016/s0300-2977(98)00143-0
  2. Hart RG, Kanter MC. Hematologic disorders and ischemic stroke. A selective review. Stroke [Internet]. 1990;21(8):1111–21. Available from: https://doi.org/10.1161/01.str.21.8.1111
  3. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos: Order out of chaos. Cancer [Internet]. 2009;115(17):3842–7. Available from: https://doi.org/10.1002/cncr.24440
  4. Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med [Internet]. 2005;352(17):1779–90. Available from: https://doi.org/10.1056/NEJMoa051113
  5. Rose SR, Petersen NJ, Gardner TJ, Hamill RJ, Trautner BW. Etiology of thrombocytosis in a general medicine population: analysis of 801 cases with emphasis on infectious causes. J Clin Med Res [Internet]. 2012;4(6):415–23. Available from: https://doi.org/10.4021/jocmr1125w
  6. Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol [Internet]. 2008;83(5):359–62. Available from: https://doi.org/10.1002/ajh.21129
  7. Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol [Internet]. 1990;8(3):556–62. Available from: https://doi.org/10.1200/JCO.1990.8.3.556
  8. Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol [Internet]. 1991;85(3):124–7. Available from: https://doi.org/10.1159/000204873
  9. Silvennoinen O, Hubbard SR. Molecular insights into regulation of JAK2 in myeloproliferative neoplasms. Blood [Internet]. 2015;125(22):3388–92. Available from: https://doi.org/10.1182/blood-2015-01-621110
  10. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood [Internet]. 2009;114(5):937–51. Available from: https://doi.org/10.1182/blood-2009-03-209262
  11. Harrison CN, Butt N, Campbell P, Conneally E, Drummond M, Green AR, et al. Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. Br J Haematol [Internet]. 2014;167(3):421–3. Available from: https://doi.org/10.1111/bjh.12986
  12. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients: An international internet-based survey of 1179 MPD patients. Cancer [Internet]. 2007;109(1):68–76. Available from: https://doi.org/10.1002/cncr.22365
  13. Beer PA, Green AR. Chapter 87. Essential thrombocythemia. In: Lichtman MA, Kipps TJ, Seligsohn U, et al, editors. Williams Hematology . 8th ed. New York: McGraw-Hill; [Accessed May 15, 2012]. Available from: AccessMedicine.
  14. Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica [Internet]. 2008;93(11):1645–51. Available from: https://doi.org/10.3324/haematol.13346
  15. Arboix A, Besses C, Acín P, Massons JB, Florensa L, Oliveres M, et al. Ischemic stroke as first manifestation of essential thrombocythemia. Report of six cases: Report of six cases. Stroke [Internet]. 1995;26(8):1463–6. Available from: https://doi.org/10.1161/01.str.26.8.1463
  16. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med [Internet]. 1995;332(17):1132–6. Available from: https://doi.org/10.1056/NEJM199504273321704
  17. Wu KK. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med [Internet]. 1978;88(1):7–11. Available from: https://doi.org/10.7326/0003-4819-88-1-7
  18. Karkucak M, Yakut T, Ozkocaman V, Ozkalemkas F, Ali R, Bayram M, et al. Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera. Mol Biol Rep [Internet]. 2012;39(9):8663–7. Available from: https://doi.org/10.1007/s11033-012-1721-x
  19. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood [Internet]. 2014;124(16):2507–13; quiz 2615. Available from: https://doi.org/10.1182/blood-2014-05-579136
  20. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol . 1992;19(3 Suppl 9):1–10.
  21. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med [Internet]. 2005;353(1):33–45. Available from: https://doi.org/10.1056/NEJMoa043800

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.